- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00391638
Efficacy and Tolerance of Peg-interferon Alpha 2a Added to Tenofovir and Emtricitabine in AgHBe Positive HBV-HIV Co-infected Patients (HB01EMVIPEG)
January 14, 2015 updated by: French National Agency for Research on AIDS and Viral Hepatitis
Pilot Study on Efficacy and Tolerance of Peg-interferon Alpha-2a (Pegasys) Added to Tenofovir DF and Emtricitabine (Truvada) in AGHBe Positive HBV-HIV Co-infected Patients. ANRS HB 01 EMVIPEG.
HBe seroconversion is an important goal for anti-HBV treatment, since it is associated with a non progressive liver infection and a better clinical outcome.
However, the rate of HBe seroconversion is low in HIV-HBV co-infected patients, mostly treated by tenofovir and emtricitabine.
This study will evaluate the efficacy and the safety of a one-year Peg-interferon alpha 2a additional treatment in patients already treated by tenofovir and emtricitabine without reaching HBe seroconversion.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Many HBV-HIV co-infected patients are currently treated with dual activity drugs such as tenofovir and emtricitabine, often in combination.
However, despite the potent antiviral activity of these drugs, the rate of HBe seroconversion is quite low, and not always sustained over time.
HBe seroconversion is an important goal for anti-HBV treatment, since it is associated with a non progressive liver infection and a better clinical outcome.
On the other hand, treatments with antiviral and immuno-modulator activity such as Peg-interferon, are infrequently used in co-infected patients, despite promising data in the field of HBV mono-infection with increased rates and sustained HBe seroconversions.
This pilot study will evaluate the efficacy and the safety of a one-year Peg-interferon alpha 2a additional treatment (180 micro-g once a week, by injection), in 55 patients already treated by tenofovir and emtricitabine for at least 6 months, and who did not reached HBe seroconversion
Study Type
Interventional
Enrollment (Actual)
56
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Dijon cedex, France, 21079
- Service des Maladies Infectieuses CHU
-
Lyon Cedex 02, France, 69288
- Service d'Hépato-Gastroentérologie Hopital Hôtel-Dieu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- HIV infection
- Karnofsky above 80 per cent
- Stable ARV since 4 months
- CD4 above 200 per mm3
- ARN VIH below 10000 copies per ml
- hepatitis B chronic with : positive antigenaemia HBe and negative antiHBe, positive DNA HBV before or under tenofovir treatment, DNA HBV negative or below 10000 copies per ml at W-8.
- Previous treatment by tenofovir and lamivudine or emtricitabine more than 6 months
Exclusion Criteria:
- HIV 2 infection
- Hepatitis C or D
- Opportunistic infection
- Alcool consummation more than 50g/d
- Cirrhosis
- Pregnancy or plan of pregnancy
- Breastfeeding
- Immunosuppressive or modulating of the immune response treatment
- Other Hepatitis B treatments than tenofovir, lamivudine or emtricitabine since 6 months
- Malabsorption
- Exclusive HIV therapy with Truvada
- Evolutive cancer under chemotherapy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: HIV antiretroviral therapy, TRUVADA , PEGASYS 180μg
Week-8 up Week0: HIV antiretroviral therapy Week 0 up Week 48: HIV antiretroviral therapy + TRUVADA + PEGASYS 180μg Week 48 up Week 72: HIV antiretroviral therapy + TRUVADA Week 72 up Week 144: HIV antiretroviral therapy
|
Truvada ® (200 mg tablet of 300 mg of emtricitabine + tenofovir DF) Dosage 1 tablet taken orally once a day
Pegasys ® injection 180μg Dosage: A subcutaneous injection per week
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
proportion of patients with seroconversion HBe (loose of HBe antigen and acquisition of HBe antibody) and HBV DNA below 2.3 log10 copies per ml
Time Frame: at Week 72
|
at Week 72
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
proportion of patients with negative HBe antigen.
Time Frame: at Week 72 and Week 144
|
at Week 72 and Week 144
|
|
proportion of patients with HBV DNA under 2.3 log 10 copies per ml.
Time Frame: at Week 72 and Week 144
|
at Week 72 and Week 144
|
|
proportion of seroconversion HBs.
Time Frame: at Week 72 and Week 144
|
at Week 72 and Week 144
|
|
proportion of patients with no more HBs antigen.
Time Frame: at Week 72 and Week 144
|
at Week 72 and Week 144
|
|
proportion of patients with HBV DNA below 2.3 log 10 copies per ml in relation with 3TC resistance or not before tenofovir treatment; increased of ALT before tenofovir treatment;duration of tenofovir treatment before study.
Time Frame: before tenofovir treatment, duration of tenofovir treatment before study
|
before tenofovir treatment, duration of tenofovir treatment before study
|
|
Biological evolution and histological of hepatic activity and fibrosis.
Time Frame: at day 0 and Week 72
|
at day 0 and Week 72
|
|
Biochemical response (ALT at normal value).
Time Frame: at Week 72 and Week 144
|
at Week 72 and Week 144
|
|
proportion of patients with :seroconversion HBe and HBV DNA below 2.3 log 10 copies per ml
Time Frame: at Week 48
|
at Week 48
|
|
HBV and HIV resistance mutations to tenofovir DF and Emtricitabine.
Time Frame: at Week 72
|
at Week 72
|
|
Immunological and virological evolution of HIV infection.
Time Frame: between Day 0 and Week 144
|
between Day 0 and Week 144
|
|
Safety
Time Frame: between Day 0 and Week 144
|
between Day 0 and Week 144
|
|
Quality of life
Time Frame: Day 0, Week 12, Week 24, Week 48, Week 72
|
Day 0, Week 12, Week 24, Week 48, Week 72
|
|
Treatment adherence
Time Frame: Day 0 to Week 144
|
Day 0 to Week 144
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Lionel Piroth, MD, Centre Hospitalier Universitaire Dijon
- Study Chair: Fabrice Carrat, MD, Inserm U 707 Paris France
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2007
Primary Completion (Actual)
May 1, 2011
Study Completion (Actual)
October 1, 2012
Study Registration Dates
First Submitted
October 23, 2006
First Submitted That Met QC Criteria
October 23, 2006
First Posted (Estimate)
October 24, 2006
Study Record Updates
Last Update Posted (Estimate)
January 15, 2015
Last Update Submitted That Met QC Criteria
January 14, 2015
Last Verified
January 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Liver Diseases
- Hepatitis, Viral, Human
- Hepadnaviridae Infections
- DNA Virus Infections
- Hepatitis B
- Hepatitis
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Antineoplastic Agents
- Tenofovir
- Interferons
- Emtricitabine
- Peginterferon alfa-2a
- Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
Other Study ID Numbers
- 2006-004137-15
- ANRS HB 01 EMVIPEG
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.